Richard A. Young Sells 34,837 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 34,837 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $5.12, for a total transaction of $178,365.44. Following the sale, the director now directly owns 8,000 shares of the company’s stock, valued at $40,960. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock opened at $5.00 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.01 and a quick ratio of 3.01. Syros Pharmaceuticals, Inc. has a 1-year low of $2.09 and a 1-year high of $8.17. The firm has a fifty day moving average of $5.29 and a two-hundred day moving average of $6.08.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same quarter last year, the company posted ($0.85) earnings per share. On average, sell-side analysts anticipate that Syros Pharmaceuticals, Inc. will post -3.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SYRS. Bain Capital Life Sciences Investors LLC grew its holdings in Syros Pharmaceuticals by 29.4% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company’s stock worth $21,421,000 after acquiring an additional 625,114 shares in the last quarter. Avidity Partners Management LP grew its holdings in Syros Pharmaceuticals by 5.8% during the 4th quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company’s stock worth $13,037,000 after acquiring an additional 92,396 shares in the last quarter. Flagship Pioneering Inc. grew its holdings in Syros Pharmaceuticals by 30.2% during the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company’s stock worth $10,079,000 after acquiring an additional 300,000 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at about $2,799,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Syros Pharmaceuticals by 576.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company’s stock valued at $909,000 after buying an additional 144,869 shares during the period. 91.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYRS has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, June 26th. Finally, StockNews.com raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 15th.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.